Therefore, it is conceivable that genomic instability mediated by deficiency in BRCA1 and BRCA2 may give rise to immunophenotype in breast cancer predictive of response to immunotherapy such as increased expression of PD-L1 and PD-1 and higher abundance of tumour-infiltrating immune cells. This evidence concerns the gene PDCD1 and neoplasm.